Literature DB >> 27106168

Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes.

Melanie Clarke1, Sara Razmjou1, Natalie Prowse1, Zach Dwyer1, Darcy Litteljohn1, Rowan Pentz1, Hymie Anisman1, Shawn Hayley2.   

Abstract

Considerable recent attention has focused on the rapid antidepressant effects observed in treatment resistant patients produced by the NMDA receptor antagonist, ketamine. Surprisingly, the effects of ketamine in the context of stressor exposure, as well as the consequences of its chronic use are unclear. Thus, we assessed the impact of acute and repeated ketamine treatment together with acute [restraint or lipopolysaccharide (LPS)] or chronic (unpredictable different psychogenic challenges) stressor exposure. Importantly, acute ketamine treatment did provoke an antidepressant-like effect in a forced swim test (FST) and this effect lasted for 8 days following repeated exposure to the drug. Although acute restraint and LPS individually provoked the expected elevation of plasma corticosterone and brain-region specific monoamine variations, ketamine had no influence on corticosterone and had, at best, sparse effects on the monoamine changes. Similarly, ketamine did not appreciably influence the stressor induced neurochemical and sucrose preference alterations, it did however, dose-dependently reverse the LPS induced elevation of the pro-inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). Likewise, repeated ketamine administration increased adult hippocampal neurogenesis. These data indicate that repeated ketamine administration had greater behavioral consequences than acute treatment and that the drug might be imparting antidepressant effects through its effects on neuroplasticity and inflammatory processes rather than the typical neurochemical/hormonal factors affected by stressors. This article is part of the Special Issue entitled 'Ionotropic glutamate receptors'.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokine; Depression; Ketamine; LPS; Neurogenesis; Stressor

Mesh:

Substances:

Year:  2016        PMID: 27106168     DOI: 10.1016/j.neuropharm.2016.04.021

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  16 in total

1.  Ketamine Alters Hippocampal Cell Proliferation and Improves Learning in Mice after Traumatic Brain Injury.

Authors:  Austin J Peters; Laura E Villasana; Eric Schnell
Journal:  Anesthesiology       Date:  2018-08       Impact factor: 7.892

2.  Tissue-selective inflammation in the oral cavity of the rat.

Authors:  Taíssa Iolanda Checón Frade; Diego Carlos Dos Reis; Geovanni Dantas Cassali; Yeshwant S Bakhle; Janetti Nogueira de Francischi
Journal:  Inflammopharmacology       Date:  2016-06-20       Impact factor: 4.473

Review 3.  Rodent ketamine depression-related research: Finding patterns in a literature of variability.

Authors:  Andrew J Polis; Paul J Fitzgerald; Pho J Hale; Brendon O Watson
Journal:  Behav Brain Res       Date:  2019-08-13       Impact factor: 3.332

4.  Peptide LCGA-17 Attenuates Behavioral and Neurochemical Deficits in Rodent Models of PTSD and Depression.

Authors:  Anton V Malyshev; Iuliia A Sukhanova; Valeria M Ushakova; Yana A Zorkina; Olga V Abramova; Anna Y Morozova; Eugene A Zubkov; Nikita A Mitkin; Vsevolod V Pavshintsev; Igor I Doronin; Vasilina R Gedzun; Gennady A Babkin; Sergio A Sanchez; Miah D Baker; Colin N Haile
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-12

5.  Hippocampal BMP signaling as a common pathway for antidepressant action.

Authors:  Elif Tunc-Ozcan; Sarah M Brooker; Jacqueline A Bonds; Yung-Hsu Tsai; Radhika Rawat; Tammy L McGuire; Chian-Yu Peng; John A Kessler
Journal:  Cell Mol Life Sci       Date:  2021-12-22       Impact factor: 9.207

6.  Lentivirus-mediated interleukin-1β (IL-1β) knock-down in the hippocampus alleviates lipopolysaccharide (LPS)-induced memory deficits and anxiety- and depression-like behaviors in mice.

Authors:  Mengmeng Li; Chenli Li; Hanjie Yu; Xiongxiong Cai; Xinbei Shen; Xin Sun; Jinting Wang; Yanhua Zhang; Chuang Wang
Journal:  J Neuroinflammation       Date:  2017-09-20       Impact factor: 8.322

7.  Ketamine: A Neglected Therapy for Alzheimer Disease.

Authors:  Neil R Smalheiser
Journal:  Front Aging Neurosci       Date:  2019-07-24       Impact factor: 5.750

8.  Anti-inflammatory and antioxidant effects of muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus.

Authors:  Monica Frinchi; Domenico Nuzzo; Pietro Scaduto; Marta Di Carlo; Maria F Massenti; Natale Belluardo; Giuseppa Mudò
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

9.  Xiaoyao Pills Prevent Lipopolysaccharide-Induced Depression by Inhibiting Inflammation and Protecting Nerves.

Authors:  Boyu Shi; Jie Luo; Yang Fang; Xiaobo Liu; Zhili Rao; Rong Liu; Nan Zeng
Journal:  Front Pharmacol       Date:  2019-11-13       Impact factor: 5.810

10.  The influence of ketamine's repeated treatment on brain topology does not suggest an antidepressant efficacy.

Authors:  Natalia Gass; Robert Becker; Jonathan Reinwald; Alejandro Cosa-Linan; Markus Sack; Wolfgang Weber-Fahr; Barbara Vollmayr; Alexander Sartorius
Journal:  Transl Psychiatry       Date:  2020-02-04       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.